To confirm the synergistic effect of RAF and STAT3 inhibitors, we evaluated their roles in the growth of KRAS mutant lung cancer cells by using AZ628 (2 μM) and BP-1-102 (10 μM). The gene discussed is RAF1; the disease is lung carcinoma.